Literature DB >> 3148785

Long-term immunosuppressive therapy of idiopathic membranoproliferative glomerulonephritis.

T Orlowski1, Z Rancewicz, M Lao, J Juskowa, J Klepacka, L Gradowska, M Morzycka-Michalik, J Glyda.   

Abstract

Fifty cases of idiopathic membranoproliferative glomerulonephritis were followed up for an average of 10 +/- 0.9 (SE) years. Forty of them, who presented a nephrotic syndrome, were treated by immunosuppressive drugs (prednisone, azathioprine, chlorambucil, cyclophosphamide) for 79 +/- 9.7 (SE) months. Cumulative survival ratio for 5, 10 and 15 years after enrollment was 0.90, 0.82 and 0.77 and after appearance of first symptoms or signs of kidney disease as determined by anamnestic data 0.97, 0.91 and 0.90 accordingly. Triple-drug therapy (prednisone and azathioprine combined with chlorambucil or cyclophosphamide) was more effective in improving proteinuria than other immunosuppressive regimens. No serious side effects were encountered.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3148785     DOI: 10.1007/bf01733447

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  16 in total

1.  [Immunosuppressive treatment of nephrotic syndrome].

Authors:  T Orlowski; J Wojtulewicz-Kurkus; J Glyda; Z Kunert
Journal:  Pol Arch Med Wewn       Date:  1968

2.  Childhood membranoproliferative glomerulonephritis: an approach to management.

Authors:  C D West
Journal:  Kidney Int       Date:  1986-05       Impact factor: 10.612

3.  [Membranoproliferative glomerulonephritis and allied glomerulonephritis: development, treatment and prognosis (author's transl)].

Authors:  K Dohi; Y Nakamoto; H Kida; T Abe; M Fujioka; N Hattori
Journal:  Nihon Jinzo Gakkai Shi       Date:  1981-02

4.  Results of a controlled drug trial in membranoproliferative glomerulonephritis.

Authors:  D C Cattran; C J Cardella; J M Roscoe; R C Charron; P C Rance; S M Ritchie; P N Corey
Journal:  Kidney Int       Date:  1985-02       Impact factor: 10.612

5.  Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy.

Authors:  J V Donadio; C F Anderson; J C Mitchell; K E Holley; D M Ilstrup; V Fuster; J H Chesebro
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

6.  The prognostic value of some clinical and histological parameters in membranoproliferative glomerulonephritis (MPGN): report of 112 cases.

Authors:  B di Belgiojoso; A Tarantino; G Colasanti; C Bazzi; L Guerra; A Durante
Journal:  Nephron       Date:  1977       Impact factor: 2.847

7.  Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children.

Authors:  A E Davis; E E Schneeberger; W E Grupe; R T McCluskey
Journal:  Clin Nephrol       Date:  1978-05       Impact factor: 0.975

8.  Idiopathic membranoproliferative (mesangiocapillary) glomerulonephritis: a clinicopathologic study.

Authors:  J V Donadio; T K Slack; K E Holley; D M Ilstrup
Journal:  Mayo Clin Proc       Date:  1979-03       Impact factor: 7.616

Review 9.  Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis.

Authors:  J S Cameron; D R Turner; J Heaton; D G Williams; C S Ogg; C Chantler; G B Haycock; J Hicks
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  2 in total

1.  Remission of resistant MPGN type I with mycophenolate mofetil and steroids.

Authors:  Sudarsana De; Dana Al-Nabhani; Paul Thorner; Daniel Cattran; Tino D Piscione; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2008-10-30       Impact factor: 3.714

2.  Outcome of patients with primary immune-complex type mesangiocapillary glomerulonephritis (MCGN) in Cape Town South Africa.

Authors:  Ikechi G Okpechi; Thandiwe A L Dlamini; Maureen Duffield; Brian L Rayner; George Moturi; Charles R Swanepoel
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.